We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Promising Cancer Immunotherapy Method Relies on Artificial Magnetic Antigen Presenting Cells

By LabMedica International staff writers
Posted on 26 Jul 2015
Print article
Image: Nanoscale artificial antigen presenting cells (nano-aAPCs) bound to receptors on the T-cell surface (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Image: Nanoscale artificial antigen presenting cells (nano-aAPCs) bound to receptors on the T-cell surface (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Image: Applying a magnetic field caused the nano-aAPCs—and their receptors—to cluster together, leading to T-cell stimulation (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Image: Applying a magnetic field caused the nano-aAPCs—and their receptors—to cluster together, leading to T-cell stimulation (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Cancer researchers have developed a method based on magnetic nanoparticles that enables the rapid extraction, enrichment, and expansion of a T-cell population that shows great promise as a tool for immunotherapy.

Adoptive immunotherapy can induce long term tumor regression, but widespread adoption of this approach has been limited by the cost and complexity of generating tumor-specific T-cells.

Investigators at Johns Hopkins University (Baltimore, MD, USA) developed an improved method for generating tumor-specific T-cells to use for adoptive immunotherapy. Their method employed paramagnetic, nanoscale artificial antigen presenting cells (aAPC) to rapidly expand tumor-specific T-cells from rare naïve precursors.

Thus far, aAPCs have been synthesized by coupling T-cell activating proteins such as CD3 or MHC-peptide to micron-sized beads. Nanoscale platforms have different trafficking and biophysical interaction properties and may allow development of new immunotherapeutic strategies. Thus, for the current study, the investigators manufactured aAPCs from biocompatible iron-dextran paramagnetic particles (50–100 nanometers in diameter).

Details of the methodology were present in a paper published in the July 14, 2015, online edition of the journal ACS Nano. The investigators mixed blood plasma from mice and, separately, humans with magnetic aAPCs that had been coated with tumor antigens. The plasma was passed through a magnetic column, and T-cells adhered to the aAPCs and were retained on the column. Other types of cells were washed through the column and discarded. The magnetic field of the column activated the T-cells, which were then washed off and cultured. After one week, their numbers had expanded by an estimated 5,000 to 10,000 times.

Senior author Dr. Jonathan Schneck, professor of pathology, medicine, and oncology at Johns Hopkins University, said, “The challenge has been to train these cells efficiently enough, and get them to divide fast enough, that we could use them as the basis of a therapy for cancer patients. We have taken a big step toward solving that problem.”

Related Links:

Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.